The first BRAF inhibitor, sorafenib (Nexavar®, developed by Bayer Pharma AG, Berlin, Germany, and Onyx Pharmaceuticals, San Francisco, CA, USA) was developed for the treatment of melanoma. This evidence concerns the gene BRAF and melanoma.